Glycan Residual Compound Biomarker Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing glycan changes in biological samples are challenging due to the complexity and number of possible glycan structures, making it difficult to use these changes as effective biomarkers for disease diagnosis and monitoring.
Innovation Solution
The method involves transforming glycans in biological samples using glycan degradation enzymes to generate populations of biomarkers, specifically non-reducing end glycan residual compounds, which are then characterized using analytical instruments to determine disease presence, identity, and severity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibodies, chromatography and/or mass spectrometry techniques are used to resolve and quantify intact or partially intact glycans, then glycan changes can be detected, but the complexity and number of possible glycan structures make the methods challenging and difficult to use as effective biomarkers
Solution Approach 1:
The patent applies segmentation by breaking down complex glycan structures into smaller, more manageable fragments through enzymatic digestion. Glycosaminoglycan lyases cleave glycans at specific bonds to generate standardized oligosaccharide fragments (such as disaccharides and trisaccharides) that are easier to analyze and quantify. This fragmentation approach reduces the complexity of the analytical task while preserving the diagnostic information needed to identify disease states.
Solution Approach 2:
The patent extracts specific diagnostic information from complex glycan populations by isolating and quantifying particular fragment types. Instead of attempting to analyze all intact glycan structures, the method extracts and measures specific oligosaccharide fragments (e.g., unsaturated disaccharides from heparan sulfate) that serve as biomarkers. This extraction approach simplifies the analysis by focusing only on the most relevant diagnostic components.
2Quantity of substance
If there are thousands of different novel glycan structures present in a single disease state, then comprehensive coverage of disease-related glycans is achieved, but each individual glycan structure is a weak marker of disease
Solution Approach 1:
The patent merges information from thousands of different glycan structures by converting them into a smaller set of standardized fragments through enzymatic digestion. Multiple different intact glycans that share common structural features are converted into the same diagnostic fragments, allowing their signals to be combined and summed. This merging process transforms many weak individual markers into a single strong composite biomarker that reflects the cumulative presence of disease-related glycans.
Solution Approach 2:
The patent applies local quality by focusing analysis on specific diagnostic regions or features within the complex glycan population. Rather than treating all glycan structures equally, the method identifies and targets specific fragment types (such as unsaturated disaccharides with particular mass-to-charge ratios) that provide the most diagnostic value. This selective focus on locally important features enhances biomarker strength while maintaining comprehensive disease coverage.
3Device complexity
If glycan degradation enzymes are used to transform glycans into biomarkers, then the complexity of analysis is reduced, but additional enzymatic treatment steps are required
Solution Approach 1:
The patent applies preliminary action by performing enzymatic digestion of glycans before the main analytical measurement step. The glycosaminoglycan lyases are applied to cleave and fragment the glycans in advance, converting complex intact structures into standardized, easily analyzable oligosaccharide fragments. This preliminary transformation simplifies the subsequent analysis by creating a more uniform and manageable sample composition, even though it adds an initial processing step.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the accurate detection and monitoring of abnormal glycan accumulation and biosynthesis, enabling effective diagnosis and treatment monitoring of diseases such as lysosomal storage diseases and cancerous conditions.
Implementation Method 1
treating a population of glycans with at least one digesting glycan enzyme to generate a population of biomarkers
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.